The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...

While some patients may view head and neck cancer screenings as an unnecessary optional screening, these exams can be ...

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Completing treatment for head and neck cancer is a milestone, but recovery is an ongoing journey. With follow-ups, ...

This guide for newly diagnosed patients provides key information to help you understand your options and have informed ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Head and neck cancer is a broad term for several types of cancers that include the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. Head and ...

In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success. The advent ...

Head and neck cancers affect the tissues of the mouth, throat, sinuses, and surrounding areas. They can impact crucial functions like breathing, swallowing, and talking. There are several types of ...